Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

No. 2 / 2025 Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with significant ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that ...

In November, Amneal received FDA approval for exenatide, its first generic injectable glucagon-like peptide-1 (GLP-1) agonist ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

Well, a global provider of genomic library and multiplexing workflow solutions, today announced the early access availability of the new MosaiXtm Library Prep Kit, designed for demanding applications ...